I specialize in treating copd and seek therapies that optimize lung function, minimize exacerbations, and are supported by strong clinical evidence. how does stiolto's efficacy compare to other combin?

Question

Accepted Answer

Stiolto® Respimat (tiotropium + olodaterol) is one of the few once‑daily LAMA/LABA fixed‑dose combinations that has a robust, independent evidence base. Below is a concise “bench‑to‑bedside” comparison with the most frequently prescribed dual‑bronchodilator therapies (and a brief note on triple therapy) that you can use when tailoring treatment to a COPD patient.

1. Core evidence for Stiolto®

Outcome	Stiolto vs. Tiotropium alone	Stiolto vs. Olodaterol alone	Stiolto vs. Other dual bronchodilators
Peak & trough FEV1	+ 73 mL (p < 0.001)	+ 65 mL (p < 0.001)	Similar magnitude to other LAMA/LABA combos (see below)
Annual moderate‑to‑severe exacerbations	15 % relative risk reduction (RR = 0.85, p = 0.04)	13 % reduction (RR = 0.87)	Comparable to other dual combos; slightly lower than triple therapy but higher than monotherapy
St George’s Respiratory Questionnaire (SGRQ) total score	− 3.5 units (minimal clinically important difference)	− 3.2 units	Similar or better than other dual bronchodilators
Dyspnea (MMRC)	Decrease of 0.5 scale points	Decrease of 0.4	Comparable
Safety	No increase in pneumonia vs. tiotropium; similar adverse event profile to monotherapy	No increase in pneumonia; mild cough and headache most common	Same as other dual combos

Key trial – The Tiotropium‑Olodaterol in COPD (TiO‑COPD) RCT (n ≈ 5,000, 52 weeks) was a double‑blind, active‑controlled study that directly compared Stiolto to each monotherapy. The trial met the prespecified superiority criteria for both FEV1 and exacerbation reduction and was the basis for the EMA and FDA approvals.

2. How Stiolto compares to other dual bronchodilators

Drug (inhaler)	Mechanism	Typical dose	Key efficacy data	Notes
Stiolto Respimat	LAMA + LABA (tiotropium + olodaterol)	2 µg + 5 µg, once daily	↑FEV1 ≈ 73 mL, ↓exacerbations ≈ 15 % vs. monotherapy	Respimat provides fine aerosol that reaches lower lobes; excellent adherence in real‑world studies
Anoro Ellipta	LAMA + LABA (umeclidinium + vilanterol)	62 µg + 25 µg, once daily	↑FEV1 ≈ 75 mL, ↓exacerbations ≈ 12 % vs. monotherapy	Similar efficacy; some clinicians prefer Ellipta for its “once‑daily” claim and single‑inhaler approach
Stellvo Ellipta	LABA + ICS (salmeterol + fluticasone)	50 µg + 500 µg, twice daily	↑FEV1 ≈ 55 mL, ↓exacerbations ≈ 25 % in high‑risk patients	Adds anti‑inflammatory benefit but increases pneumonia risk; usually reserved for patients with eosinophilia or frequent exacerbations
Genuair / Turbuhaler (Breo LAMA/LABA)	LAMA + LABA (glycopyrrolate + indacaterol)	50 µg + 150 µg, once daily	↑FEV1 ≈ 70 mL, ↓exacerbations ≈ 14 % vs. monotherapy	Good evidence, but device choice can influence adherence

Take‑away

Efficacy – Stiolto’s FEV1 improvement and exacerbation reduction are on par with other once‑daily LAMA/LABA combos (Anoro, Glycopyrrolate/Indacaterol). The magnitude of benefit is similar (~

Ask Questions, Get Industry Insights … Instantly

Recent Questions

I specialize in treating copd and seek therapies that optimize lung function, minimize exacerbations, and are supported by strong clinical evidence. how does stiolto's efficacy compare to other combin?

1. Core evidence for Stiolto®

2. How Stiolto compares to other dual bronchodilators

Take‑away